Adult Congenital Heart ♥ Association

Webinars Presents:

Life After the Fontan

Monday, November 11, 2019, 7 p.m. – 8 p.m. EST

Presenter: Yuli Kim, MD

About the Webinar

Do you know that most children who had the Fontan procedure go on to lead full and healthy lives as adults? Do you have questions about living life as an adult with a Fontan? Do you wonder about potential health issues later in life? If so, you don't want to miss this webinar. Dr. Yuli Kim, Medical Director of the Philadelphia Adult Congenital Heart Center, will talk about family planning and pregnancy, liver health, and exercise, as well as living a healthy lifestyle. She will also cover the topic of the potential need for transplant down the line. Register today.

REGISTER NOW: https://bit.ly/2nvJLjB

About the Presenter

Yuli Kim, MD, is the medical director of the Philadelphia Adult Congenital Heart Center, a joint program of the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania. She completed a residency in Internal Medicine at Johns Hopkins Hospital and fellowship in Cardiovascular Medicine at the Cleveland Clinic before subspecialty training in Adult Congenital Heart Disease with the Boston Adult Congenital Heart program. She has been at the Philadelphia Adult Congenital Heart Center since 2010. She is a member of the ACHA Medical Advisory Board and co-chair of the MAB Patient/Family Program Committee.

About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA or visit www.achaheart.org.

Sponsorship support provided by Actelion Pharmaceuticals US, Inc., and Gilead Sciences.